BOMAC GLUCALMAX-METABOLIC TREATMENT FOR CATTLE

Main information

  • Trade name:
  • BOMAC GLUCALMAX-METABOLIC TREATMENT FOR CATTLE
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • BOMAC GLUCALMAX-METABOLIC TREATMENT FOR CATTLE
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • CATTLE | BEEF | BOS INDICUS | BOS TAURUS | BOVINE | BUFFALO | BULL | BULLOCK | CALF | COW | DAIRY COW | HEIFER | STEER
  • Therapeutic area:
  • NUTRITION & METABOLISM
  • Therapeutic indications:
  • MILK FEVER

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered
  • Authorization number:
  • 36027
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

MATERIAL SAFETY DATA SHEET Page1of4

MATERIAL SAFETY DATA SHEET (MSDS)

BOMAC Laboratories Limited urges recipient of this MSDS to study it carefully

to become aware of, and understand, the hazards associated with the product.

To promote safe handling, each recipient should notify its employees, agents and

others who will use this material and any other information regarding hazards or safety.

Page 1 of 3

_____________________________________________________________________________

IDENTIFICATION

_____________________________________________________________________________

Product Name: Glucalmax UN Number : Free

Other Names: N/A Dangerous Goods Class: N/A

Animal Remedies Board (ARB) Subsidiary Risk: N/A

Product Licence Number: 1441 HAZCHEM Code: N/A

Toxic Substances Schedule: N/A

Use: For the treatment of milk fever and milk fever complicated by acetonaemia and grass

staggers in cattle.

Physical Description: Clear, practically colourless liquid with no more than a slight odour.

Active Ingredients: Calcium Borogluconate CAS* 5743-34-0 250g/Litre

Dextrose CAS* 14431-43-7 250g/Litre

Magnesium Chloride CAS* 7786-30-3 80g/Litre

Manufacturer: BOMAC Laboratories Ltd

Cnr Wiri Station Road & Hobill Avenue

P O Box 76-369, Manukau City, Auckland, New Zealand

Phone: (09) 262-3169 Facsimile: (09) 262-3008

_____________________________________________________________________________

HEALTH HAZARD INFORMATION

MATERIAL SAFETY DATA SHEET Page 2 of 4

_____________________________________________________________________________

HEALTH EFFECTS

Swallowed: May cause vomiting and diarrhoea, an erythematous rash followed by desquamation,

and stimulation of the nervous system followed by depression.

Eye: May cause transient stinging or redness.

*CAS, Chemical Abstracts Service Registry Number

PRODUCT: GLUCALMAX ARB Licence No: 1441 Page 2 of 3

_____________________________________________________________________________

Skin: Product is not considered to be a skin irritant.

Inhaled: No inhalation hazard identified from data found.

FIRST AID

Swallowed: Induce vomiting. Seek medical advice.

Eye: Flush out with a gentle stream of clean water for 15 minutes. Seek medical advice if stinging

or redness persists.

Skin: Wash contact areas with water. Remove contaminated clothing and launder before reuse.

Inhalation: Remove from further exposure. If unconsciousness occurs, seek immediate medical

attention. If breathing has stopped, use mouth to mouth resuscitation.

_____________________________________________________________________________

PRECAUTIONS FOR USE

_____________________________________________________________________________

Exposure Limits: Not established. Use only as directed.

Ventilation: No special ventilation is recommended under normal conditions of use. No special

respiratory protection equipment is recommended under normal conditions of use with sufficient

ventilation.

Personal Protection: Avoid eye and skin contact. Wear eye protection (face visor or goggles) if

accidental eye contact can occur. Observe good personal hygiene.

Flammability: Non flammable. Keep well away from heat and keep container closed when not in

use.

_____________________________________________________________________________

MATERIAL SAFETY DATA SHEET Page 3 of 4

SAFE HANDLING INFORMATION

_____________________________________________________________________________

Storage and Transport:

Store below 25°C. Protect from light. Containers should always be kept closed in storage and

properly labelled. Store only in original containers.

PRODUCT: GLUCALMAX ARB Licence No:1441 Page 3 of 3

_____________________________________________________________________________

Spills and Disposal: Remove with liquid binding material (eg sand, sawdust, or diatomaceous

earth). Wash the residue from the contaminated area with water. Dispose of waste in compliance

with local waste disposal regulations. Small quantities and residues may be flushed into drains.

Fire/Explosion Hazard:

The product is non flammable. Use alcohol foam, CO

, dry powder, water or BCF fire

extinguishers. Use water sprays to cool fire exposed surfaces and any adjacent storage vessels.

_____________________________________________________________________________

Sheet Dated: 06 March 1996 Supersedes Sheet Dated: 15 October 1993

_____________________________________________________________________________

Contact Point:

Dr Bruce Vautier B.V.Sc

Manager, Technical Services

BOMAC Laboratories Ltd

Cnr Wiri Station Road & Hobill Avenue

PO Box 76-369, Manukau City, Auckland,

New Zealand

MATERIAL SAFETY DATA SHEET Page 4 of 4

Phone: (09) 262-3169

Facsimile: (09) 262-3008

Additional Information:

National Poisons Information Centre OR Contact your local Poisons

University of Otago, Medical School Information Centre for

PO Box 913 further advice.

Dunedin

New Zealand

Phone (03) 474 7000

________________________________________

The information in this data sheet is to the best of our knowledge, representative of the product.

As conditions of use are beyond the control of BOMAC Laboratories Ltd no legal responsibility is

accepted for the use of this information.

7-12-2018

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Magnesium citrate malate as a source of magnesium added for nutritional purposes to food supplements

Published on: Thu, 06 Dec 2018 The present scientific opinion deals with the assessment of the bioavailability of magnesium, from the proposed nutrient source, magnesium citrate malate (MgCM), when added for nutritional purposes to food supplements. MgCM is a mixed salt consisting of magnesium cations and citrate and malate anions, and with a magnesium content of 12–15%. MgCM is proposed to be used in food supplements that are intended to provide up to 300–540 mg/day magnesium. The data provided demonst...

Europe - EFSA - European Food Safety Authority Publications

29-10-2008

Reassessment of reimbursement status for medicinal products in ATC group C08CA

Reassessment of reimbursement status for medicinal products in ATC group C08CA

The Danish Medicines Agency has assessed the question of the future reimbursement status for medicinal products in ATC group C08CA (dihydropyridine calcium channel blockers) which are used for the treatment of cardiovascular diseases.

Danish Medicines Agency

14-2-2008

Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases

Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases

Following a request from the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status for medicinal products authorised for marketing in Denmark in ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

18-12-2018


Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801

Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801

Calcium chloride / glutamic acid / glutathione / histidine / lactobionic acid / magnesium chloride / mannitol / potassium chloride / sodium hydroxide: List of nationally authorised medicinal products - PSUSA/00010390/201801

Europe - EMA - European Medicines Agency

27-11-2018


Opinion/decision on a Paediatric investigation plan (PIP): Fibrinogen,thrombin,aprotinin,calcium chloride, decision type: , therapeutic area: , PIP number: P/0199/2018

Opinion/decision on a Paediatric investigation plan (PIP): Fibrinogen,thrombin,aprotinin,calcium chloride, decision type: , therapeutic area: , PIP number: P/0199/2018

Opinion/decision on a Paediatric investigation plan (PIP): Fibrinogen,thrombin,aprotinin,calcium chloride, decision type: , therapeutic area: , PIP number: P/0199/2018

Europe - EMA - European Medicines Agency